Nextage Therapeutics Ltd (TLV:NXTG)
Israel · Delayed Price · Currency is ILS · Price in ILA 35.80
-3.10 (-7.97%)
Sep 23, 2026, 5:32 PM IDT
Nextage Therapeutics Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.51 | 3.6 | 3.23 | 7.63 | - | 0.09 | |
Revenue Growth | -17.77% | 11.57% | -57.71% | - | - | -52.36% |
Cost of Revenue | 3.31 | 3.3 | 3.95 | 6.47 | - | 0.08 |
Gross Profit | -0.8 | 0.3 | -0.72 | 1.16 | - | 0.02 |
Selling, General & Admin | 8.93 | 6.22 | 3.66 | 4.36 | 4 | 5.08 |
Research & Development | 2.57 | 2.23 | 1.09 | 2.11 | 1.85 | 2.06 |
Operating Expenses | 11.5 | 8.45 | 4.75 | 6.48 | 5.85 | 7.14 |
Operating Income | -12.3 | -8.15 | -5.47 | -5.32 | -5.85 | -7.12 |
Interest Expense | -2 | -1.54 | -0.53 | -0.14 | -0.03 | -0.03 |
Interest & Investment Income | - | - | 0.05 | - | 0.02 | - |
Earnings From Equity Investments | - | -0.04 | -0.83 | - | 0.02 | -0.06 |
Currency Exchange Gain (Loss) | -0.28 | -0.28 | -0.14 | -0.02 | -0.16 | 0.18 |
Other Non Operating Income (Expenses) | -1.39 | -1.39 | -1.91 | -2.09 | 0.01 | -0.34 |
EBT Excluding Unusual Items | -15.97 | -11.4 | -8.82 | -7.57 | -5.99 | -7.38 |
Impairment of Goodwill | - | - | - | - | - | -0.56 |
Gain (Loss) on Sale of Investments | - | 5.12 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 10.74 | - | - |
Pretax Income | -15.97 | -6.28 | -8.82 | 3.17 | -5.99 | -7.93 |
Earnings From Continuing Operations | -15.97 | -6.28 | -8.82 | 3.17 | -5.99 | -7.93 |
Earnings From Discontinued Operations | - | - | - | -3.53 | - | - |
Net Income to Company | -15.97 | -6.28 | -8.82 | -0.36 | -5.99 | -7.93 |
Minority Interest in Earnings | 0.13 | 0.21 | - | 2.26 | 0.4 | 0.21 |
Net Income | -15.84 | -6.06 | -8.82 | 1.89 | -5.59 | -7.73 |
Net Income to Common | -15.84 | -6.06 | -8.82 | 1.89 | -5.59 | -7.73 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 73 | 42 | 52 | 29 | 28 | 26 |
Shares Outstanding (Diluted) | 73 | 42 | 52 | 29 | 28 | 26 |
Shares Change | 97.94% | -19.42% | 77.80% | 4.79% | 6.98% | 127.75% |
EPS (Basic) | -0.22 | -0.14 | -0.17 | 0.06 | -0.20 | -0.30 |
EPS (Diluted) | -0.22 | -0.14 | -0.17 | 0.06 | -0.20 | -0.30 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -10.57 | -6.51 | 0.65 | -3.42 | -6.02 | -3.97 |
Free Cash Flow Per Share | -0.15 | -0.16 | 0.01 | -0.12 | -0.22 | -0.15 |
Gross Margin | -31.89% | 8.28% | -22.42% | 15.15% | - | 17.58% |
Operating Margin | -489.57% | -226.46% | -169.67% | -69.76% | - | -7825.28% |
Profit Margin | -630.69% | -168.48% | -273.49% | 24.84% | - | -8492.31% |
Free Cash Flow Margin | -420.78% | -180.91% | 20.12% | -44.89% | - | -4367.03% |
EBITDA | -11.81 | -7.65 | -5.17 | -3.6 | -5.79 | -6.93 |
EBITDA Margin | - | -212.65% | -160.22% | -47.23% | - | - |
D&A For EBITDA | 0.49 | 0.5 | 0.31 | 1.72 | 0.06 | 0.19 |
EBIT | -12.3 | -8.15 | -5.47 | -5.32 | -5.85 | -7.12 |
EBIT Margin | - | -226.46% | -169.67% | -69.76% | - | - |